SM
WHWK

Sciencast Management’s Whitehawk Therapeutics WHWK Stock Holding History

Sciencast Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,513
Closed -$201K – 711
2022
Q1 		$201K Buy
+11,513
New +$221K 0.05% 406

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Sciencast Management's WHWK Position: Q2 2022 in Review

Sciencast Management sold out of Whitehawk Therapeutics (WHWK) in Q2 2022, closing a stake of 11,513 shares — an estimated $201K sold.

Sciencast Management first reported a position in WHWK in Q1 2022 and held it in 1 quarter. The position peaked at $201K in Q1 2022. 68 funds tracked by Wall St. Rank hold WHWK as of Q2 2022.

  • Sciencast Management reported no remaining Whitehawk Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sciencast Management sold 11,513 Whitehawk Therapeutics shares in Q2 2022, an estimated $201K.
  • Sciencast Management first reported a position in Whitehawk Therapeutics in Q1 2022 and held it in 1 quarter.
  • Sciencast Management's Whitehawk Therapeutics position peaked at $201K in Q1 2022.
  • 68 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2022.

Based on Sciencast Management's 13F filing for Q2 2022, filed 3 Aug 2022.